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Bruton’s Tyrosine Kinase (BTK) is highly expressed and activated in more than 90% of acute 
myeloid leukemia (AML) cases (1, 2). An important contribution of BTK has been reported in 
the context of FLT3-ITD positive AML (2) and is involved in signaling pathways of TLRs (3), 
NFκB (2) and chemokine receptor CXCR4 (4). Expression and activation of BTK are 
associated with poor prognosis of AML patients (2, 5). The mixed lineage leukemia (MLL) 
gene is frequently disrupted by chromosomal rearrangements and is associated with distinct 
clinical features and poor prognosis. Human cord blood hematopoietic CD34+ progenitor 
cells transduced with MLL-AF9 (MA9) maintain a myelomonocytic AML-like phenotype in 
cytokine-supplemented medium (6). The cells induce leukemia in NOD/SCID mice 
representing a human model of MA9 positive leukemia (6). The specific contribution of BTK 
in MLL-rearranged AML (MLL-AML) is not known. Because an essential role of NFκB 
signaling by MLL oncoproteins in the maintenance of leukemic stem cells was reported (7), 
we investigated the contribution of BTK and p65 in MLL rearranged leukemia. 
Whole cell lysates (WCL) from AML cell lines (Figure 1A, left panel), cord blood CD34+ cells 
(CB1 and 2), MA9 clones 3 and 6 (MA9.3 and 9.6) (Figure 1A, middle panel) and leukemic 
blasts from MLL-AML patients and CB2 (Figure 1A, right panel and Supp. Table 1) were 
probed for the expression and phosphorylation of p65 (pS536) and BTK (pY223). 
Interestingly, AML cell lines with MLL-rearrangements (MOLM-13 and THP-1), both MA9 
clones and AML patients (AML2 and 3) indicated constitutive phosphorylation of both p65 
and BTK, albeit to different degrees. Importantly, short-term treatment of MA9.3 cells with 
BTK specific Inhibitor, Ibrutinib, inhibited the phosphorylation of BTK and p65 in a dose-
dependent manner in MA9.3 and MOLM-13 cells (Figure 1B and Supp. Figure 1), positioning 
BTK upstream of NFκB. NFκB transactivation assay demonstrated that p65 is 
transcriptionally active in MOLM-13, THP-1, NOMO and MA9.3 cells in comparison to OCI 
AML3 (Figure 1C). Activated p65 is reported to induce the expression of BTK in Bortezomib-
resistant multiple myeloma cell lines and primary malignant plasma cells (8). That study 
indicated the presence of two p65 binding sites in BTK promoter region. These observations 
led us to investigate the involvement of activated p65 in regulating the expression of BTK. 
We performed luciferase-based BTK promoter assays with empty (pGL4) or test construct 
(pGL4-BTK). MOLM-13 and MA9.3 cells electroporated with pGL4-BTK vector revealed 
substantially elevated luciferase activity demonstrating the transcriptional activity of p65 
(Supp. Figure 2A, left panel). Interestingly Ibrutinib treatment suppressed BTK promoter 
activity in these cell lines (Supp. Figure 2A, right panel). OCI AML3 cells with a lower level of 
activated p65 indicated minimal luciferase activity (Supp. Figure 2A, left panel). Additionally, 
MA9.3 cells treated with a proteasomal inhibitor (MG-132) or NFκB inhibitor (BAY 11-7082) 
reduced BTK expression in a dose-dependent manner, again indicating the involvement of 
activated p65 in regulation of BTK expression (Supp. Figure 2B). Taken together, our data 
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identify BTK as one of the kinase’s involved in the phosphorylation of p65 subsequently 
regulating its expression. Given the promising results associated with Ibrutinib treatment in 
the context of FLT3-ITD cell lines and AML patient material (2, 5, 9), we sought to determine 
the cytotoxic effect of BTK inhibition in MLL rearranged leukemia. Control (CB-CD34+) and 
MA9.3 cells were treated with increasing doses of Ibrutinib (0.25, 0.5, 1.0 and 2µM) and cell 
viability was analyzed (Figure 1D, left panel). Ibrutinib treatment (≥ 0.5µM) significantly 
reduced the viability of MA9.3 cells as compared to DMSO-treated cells. Ibrutinib treatment 
affected MA9.3 cell metabolism (ability to reduce tetrazolium dye) (Supp. Figure 3A), 
induced cell cycle arrest (Supp. Figure 3B) and suppressed colony formation (Supp. Figure 
3C) in a dose-dependent manner. Of note, IBR treatment had no effect on cell cycle 
distribution (Supp. Figure 3D) and failed to induce cell death (Supp. Figure 3E) in the non-
MLL rearranged AML cell line, OCI AML-3. Daunorubicin (a standard chemotherapy drug in 
AML) in combination with Ibrutinib further sensitized the cells and induced a strong effect on 
cell viability (Figure 1D, right panel). The nature of drug interaction (Ibrutinib: Daunorubicin) 
was analyzed by calculating the coefficient of drug interaction (CDI) value (10). CDI values 
<1.0 indicated that Daunorubicin synergistically increased the cytotoxic efficacy of Ibrutinib 
(Supp. Table 2). Control cells treated under identical conditions were nonresponsive to 
Ibrutinib treatment. Collectively, the data indicate a pivotal role for activated BTK in MLL-
rearranged leukemic cells and inhibition of BTK activity affected cell viability in MA9.3 cells. 
RAC GTPases (RAC1, RAC2, and RAC3) act as a molecular switch in multiple cellular 
processes that affect cancer progression, cell cycle progression, cell survival and including 
cytoskeletal dynamics (11). Previous studies have established a positive relationship 
between small Rho GTPases Rac1, 2 and MA9 rearrangements (6, 12). BTK plays an 
important role in the migration of mouse bone marrow-derived mast cells in response to 
chemo-attractants via RAC activation (13). It is therefore tempting to speculate on a role for 
BTK in the activation of RAC1. RAC1-GTPase activation assays were performed in MA9.3 
cells treated with DMSO and Ibrutinib (Figure 2A). In line with observations by others (6, 12), 
we identified RAC1-GTP in DMSO treated cells. Interestingly, Ibrutinib treatment significantly 
reduced RAC1 activation. Similar data were observed in MOLM-13 cells but not in non-MLL 
rearranged cell line OCI AML3 (Supp. Fig. 4A and B). The findings thus underscore the 
contribution of activated BTK in the activation of RAC1-GTPase. RAC inhibitor treatment, 
NSC23766, affected MA9.3 cell viability (6, 12). Since BTK lies upstream of RAC1 and is 
playing a functional role in cell survival (Figure 1B and 1D), we hypothesized that Ibrutinib 
treatment might increase the efficacy of RAC inhibition. MA9.3 cells were treated with 
various doses of NSC23766 (5, 10, 15 and 20 µM) alone or in combination with clinically 
relevant doses of Ibrutinib (0.5µM) (Figure 2B). The drugs were more potent in combination 
and CDI values indicated synergism between NSC23766 and Ibrutinib (CDI < 1.0) (Supp. 
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Table 3). Again, control cells (CB-CD34+) were inert to the inhibitor treatment. Of note, 
short-term NSC23766 treatment did not affect p65 phosphorylation, suggesting RAC1 
inhibition-induced cell death is independent of changes in p65 phosphorylation (Supp. Figure 
5). These observations collectively highlight the dependency of the MA9.3 cells on BTK 
activation and its downstream signaling for cell survival. Bone marrow stroma and stromal 
cell-derived soluble factors have been implicated in the cytoprotection of AML cells (2, 14). 
So we further investigated in this direction. Short-term treatment of serum-starved MA9.3 
with HS5 conditioned medium resulted in the phosphorylation of BTK and p65 (Supp. Figure 
6A-C). Gαq protein directly stimulated the activity of purified BTK (15). Furthermore, an 
important role for CXCR4 and Notch signaling in the hematopoietic stem cell 
microenvironment has also been described (16, 17). Therefore, we used pharmacological 
inhibitors to disrupt signaling at the receptor level (CXCR4 antagonist AMD3100, Gamma-
Secretase inhibitor XII (GSI XII) to block Notch activation) and at the level of heterotrimeric G 
protein function (FR900359 and BIM46187) (18, 19). MA9.3 cells were pretreated with 
various inhibitors and analyzed for activation of BTK and p65 (Supp. Fig. 6D and E). 
Interestingly, pan G protein inhibitor BIM46187 induced phosphorylation of BTK and p65, 
whereas no such effect was noted using Gαq/11 specific inhibitor FR900359, AMD3100 or 
GSI XII. The inhibitors also failed to block phosphorylation on BTK and p65, indicating the 
Gαq/11 family of G proteins, CXCR4 and Notch signaling is not involved in activation of BTK 
and p65. We next used human bone marrow stromal cells (HS5) and primary stromal cells 
and investigated whether BTK-RAC1 inhibition would block the protective effects of stromal 
cells. Compared to MA9.3 cells without stromal cell support, MA9.3 cells cocultured with 
HS5 (Supp. Figure 7A) or primary bone marrow stromal cells (Supp. Figure 7B) were 
resistant to the cytotoxic action of Ibrutinib and showed reduced cytotoxicity to NSC23766. 
However, in comparison to single drug treatment, a combination of Ibrutinib and NSC23766 
demonstrated considerable induction of cell death (Supp. Figure 7A and 7B).  
These findings expand our current understanding of the multiple mechanisms by which MLL 
rearrangements regulate cellular viability. Specifically, we demonstrate the contribution of 
aberrantly active BTK and p65 in cells with MLL rearrangements. The effect of Ibrutinib on 
MA9.3 cells indicates specific vulnerability of MLL rearranged leukemia to BTK inhibition. 
Our results may provide the basis for future clinical trials with Ibrutinib used as a single agent 
or in combination with Daunorubicin or RAC1 inhibition. This strategy might benefit MLL 
rearranged AML where there is a high risk of relapse and resistance to conventional 
chemotherapy.    
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Figure Legends 
Figure 1: BTK and p65 are activated in MLL rearranged cells and pharmacological inhibition 
of BTK induced cell death. (A) AML cell lines: OCI AML3, MOLM-13, THP-1, NOMO (left), 
cord blood-CD34+ cells (CB1), MA9 clones (MA9.3, MA9.6), FLT3 ITD+AML (ITD+AML) 
patient leukemic blasts (middle) and CB2,  MLL+AML patient leukemic blasts (AML1, 2, 3) 
(right) were lysed and immunoblotted for phospho-p65 (pS536) and -BTK (pY223) and total 
(T) proteins. GAPDH is internal loading control. ITD+AML cell lysates served as a positive 
control for the detection of phosphorylated p65 and BTK. Densitometric analysis of 
phosphorylated BTK and p65 is indicated under the blots. (B) MA9.3 cells were serum 
starved for 3 hrs and subsequently treated with 1 and 2µM Ibrutinib for additional 2 hrs. 
Whole cell lysates (WCL) were analyzed for the activation of p65 and BTK proteins. Vinculin 
is internal loading control (left). Densitometric analysis of P-p65 relative to T-p65 from three 
independent experiments is shown (right). (C) OCI AML3, MOLM-13, THP-1, NOMO and 
MA9.3 cells were lysed and transcriptionally active p65 is detected via NFκB activation 
assay following manufacturer’s instructions. Nuclear extracts from Jurkat cells stimulated 
with calcium ionophore and tissue plasminogen activator served as positive (+) control. p65 
activation from three independent experiments (in duplicates) is plotted. (D) Control CB-
CD34+ cells and MA9.3 cells were treated with DMSO or different doses of Ibrutinib (left) or 
Daunorubicin alone or in combination (right) as indicated for 48 hrs, assayed for cell viability. 
Percentage of viable cells (Annexin V and sytox blue negative) from four independent 
experiments is shown (left). Error bars indicate SEM. *p<0.05, ** p<0.01, *** p<0.001 and 
**** p<0.0001. 
Figure 2: Ibrutinib inhibits RAC1 activation and sensitized cells for NSC23766 treatment in 
MA9.3 cells. (A) MA9.3 cells were treated with Ibrutinib (2µM) for 14 hrs. GTP-RAC1 was 
enriched and detected using active GTP-RAC1 activation assay. Bound RAC1 and total 
RAC1 (upper and lower bands) were detected using RAC1 antibody (left). RAC1-GTP 
protein was densitometrically quantified. Percentage of RAC1 activation from four 
independent experiments is shown) (right). (B) Control and MA9.3 cells were treated with 
DMSO or NSC23766 or Ibrutinib as indicated for 48 hrs, assayed for cell viability (left). 
Percentage of viable cells from four independent experiments is shown. Error bars indicate 
SEM. *p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001.  
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